Working with the life sciences industries to create value / Sir Andrew Dillon, chief executive of the National Institute for Clinical Excellence (NICE)

Working with the life sciencesindustries to create valueBiocatBarcelona, 24 NB l November 2011 b

The purpose of NICE• H l th h lth service i Help the health i improve th quality of care the lit f• Increase the rate of adoption of effective and cost effective new technologies by the health system• Work with companies to help them understand what the health system needs and how the additional value that thier products bring to patients is assessed

Health technologies• Pharmaceuticals Ph ti l• Biotech• Diagnostics Di ti• Medical devices• We want to see products which bring additional diagnostic and th di ti d therapeutic b ti benefit f patients and fit for ti t d which make good use of health system resources

NICE: defining value Outcomes for patients Impact onStakeholder healthperspectives system resources Scientific and social value judgements

NICE: NICE cost effectiveness analysis t ff ti l i 1 xProbability ofrejection j Rituximab for x Imatinib for follicular lymphoma chronic myeloid leukaemia (blast phase) Trastuzumab for early stage HER-2 positive b iti breast t x cancer 0 16 32 48 64 80 Cost per QALY ($’000)

Most new health technologies bring additional valueDecisionD i i Recommendations R d iYes 276 (63%) 82% of NICE advice is positiveOptimised 83 (19%)Only in research 24 (5%)No 55 (13%)Breakdown of all decisions contained in published NICE Technology Appraisals p gy pp1–236 (January 2000 to October 2011)Note: 6 withdrawn recommendations and 10 non-submissions are not included

Helping innovators understand value• Early t E l stage scientific advice i tifi d i• Wider definition of value• Transparent and inclusive evaluative processes T t di l i l ti• Clear and detailed guidance• Targeted research questions

Scientific Advice Programme• I t Interpretation of NICE t h l t ti f technology appraisal methods i l th d guidance• Research design (study population duration population, duration, comparators, endpoint(s), type of study)• Economic evaluation design (e g form of evaluation (e.g. and approaches to benefit measurement; relevant trial(s) for economic evaluation; the use of (QALYs) ( ) ( )• Methods issues (e.g. selection of instruments / research to derive QALYs; extrapolation of long-term outcomes; planning for indirect comparisons)• Insights from existing appraisals

Value based pricing• R Recent UK G t Government proposals (to be i t d t l (t b introduced d from 2014) designed to extend the definition of value in UIK drug appraisal and reimbursement decisions decisions.• Increased focus on: – Wider societal benefits – Products which address areas of unmet need or high burden of illness – New products with particularly innovative features• Seen as an evolution of and not a replacement for the PPRS and NICE arrangements

Conclusion• I Innovators and health systems need t work t t d h lth t d to k together to th t create and deliver value for patients• We need to establish the earliest possible dialogue between companies and agencies that assess new technologies• Health systems – and the agencies that work for them have a responsibility to support innovation and to work p y pp constructively with the companies that deliver it

Working with the life sciences industries to create value / Sir Andrew Dillon, chief executive of the National Institute for Clinical Excellence (NICE)

by Biocat, BioRegion of Catalonia on Dec 12, 2011

Accessibility

Categories

Tags

Upload Details

Usage Rights

Statistics

Working with the life sciences industries to create value / Sir Andrew Dillon, chief executive of the National Institute for Clinical Excellence (NICE) — Presentation Transcript